Dr. Reddy's Biologics

What Dr. Reddy's Biologics does

Dr. Reddy's Biologics is the biologics business arm of Dr. Reddy's Laboratories Ltd (NYSE: RDY), an Indian pharmaceutical conglomerate founded in 1984. The division, established around 2001 in the United States and headquartered in Princeton, develops and commercializes biosimilars and biologic therapies, drawing on approximately 25 years of cumulative experience in biologics. Its portfolio includes an Abatacept biosimilar whose BLA was accepted by the USFDA in February 2026, positioning it for potential US market entry in autoimmune and inflammatory disease indications.

The division's pipeline extends beyond traditional biosimilars through a partnership with Coya Therapeutics to develop COYA 302, an investigational combination biologic therapy for amyotrophic lateral sclerosis (ALS), with the FDA accepting the IND application in August 2025 and Phase 2 dosing underway. Operationally, Dr. Reddy's Biologics leverages the parent company's infrastructure of 23 manufacturing facilities, 26,000+ employees, and a commercial footprint spanning 83 countries, with products reaching more than 750 million patients globally.

The business model is built on pharmaceutical product commercialization, generating revenue through the sale of biosimilar and biologic drugs distributed via pharmacy networks, wholesalers, hospitals, and healthcare systems. Pricing follows standard pharmaceutical industry mechanisms, including negotiated rates with payers and reimbursement frameworks. The division does not publicly disclose standalone revenue, as financial results are reported within the consolidated financials of Dr. Reddy's Laboratories. Strategic direction centers on expanding the biosimilars pipeline, pursuing regulatory approvals in the US and other regulated markets, and broadening into novel biologic therapies through partnerships.

Name

Dr. Reddy's Biologics

Legal name

Dr. Reddy's Laboratories, Inc.

Website

https://drreddysbiologics.com

Company type

Private

Founded year

2001

Operating status

Operating

Short description

Dr. Reddy's Biologics is the US-based biologics division of Dr. Reddy's Laboratories, developing and commercializing biosimilars and biologic therapies for autoimmune disease and ALS, serving global pharmaceutical markets through the parent's distribution infrastructure.

Ownership category

akta.pro rank

Product category

Biosimilar and Biologic Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA)

akta.pro secondary industry

Autoimmune & Rheumatology Biosimilars (HLAAAHAI)

Keywords

• Biosimilar pharmaceuticals
• Biologic therapies
• Interchangeable biosimilars
• Biopharmaceutical development
• Clinical stage biologics

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Biosimilar Product Sales: Dr. Reddy's Biologics generates revenue through the sale of biosimilar pharmaceutical products. As a subsidiary of Dr. Reddy's Laboratories, it commercializes biologic medicines including biosimilar versions of reference biologics for treatment of various diseases.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Dr. Reddy's Biologics develops and commercializes biosimilar and biologic pharmaceutical products, targeting diseases such as autoimmune disorders, oncology, and inflammatory conditions. The portfolio includes the proposed interchangeable biosimilar Abatacept (under USFDA BLA review) and the investigational biologic COYA 302 for amyotrophic lateral sclerosis (ALS), developed in partnership with Coya Therapeutics and currently in Phase 2 clinical trials.

Product overview

Dr. Reddy's Biologics is a biopharmaceutical company focused on developing and commercializing biosimilars and biologic therapies. The company's portfolio includes Abatacept Biosimilar (an interchangeable biosimilar candidate under FDA review) and COYA 302 (an investigational ALS therapy developed in partnership with Coya Therapeutics). With approximately 25 years in global biosimilars, the company leverages its presence across 83 countries with 23 manufacturing facilities to serve over 750 million patients worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Abatacept Biosimilar A proposed interchangeable biosimilar product developed by Dr. Reddy's Biologics, currently under USFDA review via a Biologics License Application (BLA). Intended for use by healthcare providers, hospitals, and pharmacy systems in the treatment of conditions for which the reference biologic Abatacept is approved.
• COYA 302 An investigational biologic therapy being co-developed by Dr. Reddy's Biologics in partnership with Coya Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS). Currently in Phase 2 clinical trials following FDA acceptance of the IND application in August 2025.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Coya TherapeuticscoreStrategic or Co-development Partner · 9 December 2025Coya Therapeutics announced enrollment of first ALS patients in the ALSTARS Trial of COYA 302. Dr. Reddy's Biologics collaborates on development of biologic therapies for amyotrophic lateral sclerosis (ALS). FDA accepted Investigational New Drug (IND) application for COYA 302 in August 2025 and Phase 2 trial began.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Amgen: Both reference biologic originator and biosimilar developer (Amjevita, Kanjinti, Mvasi) with deep biologics manufacturing expertise. Comparable as a US-headquartered player with both originator biologics and biosimilar franchises.
• Viatris: Formed via Mylan-Upjohn combination, with a biosimilar portfolio including Fulphila, Ogivri, Semglee and others. Comparable as a global pharmaceutical company with a meaningful biosimilar franchise and broad geographic reach.
• Celltrion: South Korean biosimilar pioneer commercializing infliximab, rituximab, trastuzumab and other biosimilars globally. Comparable in being a non-legacy biopharma with deep biosimilar pipeline and direct commercialization in US and EU.
• Teva Pharmaceutical Industries: Global pharmaceutical company with marketed biosimilars (Truxima, Herzuma, Ogivri co-developed) targeting autoimmune and oncology indications. Comparable as a generics-and-biosimilar player with global commercial reach.
• Coherus Biosciences: US-based biopharmaceutical company focused on biosimilars and immuno-oncology, with marketed biosimilars (Udenyca, Yusimry) and an interchangeable insulin biosimilar. Comparable as a biosimilar-focused company with US commercial ambitions.
• Biocon Biologics: Indian-headquartered biosimilar-focused subsidiary of Biocon Limited with global commercial reach in autoimmune and oncology biosimilars. Closest head-to-head comparable in geographic origin, therapeutic area focus, and global scaling ambition.
• Sandoz: Spun off from Novartis as a dedicated biosimilars and generics business, with a large marketed biosimilar portfolio including Omnitrope, Hyrimoz, Erelzi and Wyost/Jubbonti. Comparable as the global biosimilar market leader with interchangeable designations in the US.
• Samsung Bioepis: Joint venture between Samsung Biologics and Biogen focused on biosimilar development and commercialization across autoimmune and oncology reference biologics in regulated markets. Comparable as a pure-play, late-stage biosimilar developer.
• Alvotech: Iceland-based biosimilar specialist developing interchangeable biosimilars in immunology, oncology and ophthalmology, with US commercial partnerships. Comparable as a focused interchangeable biosimilar developer targeting the same reference molecules.

Broad incumbents

• Pfizer: Major multinational pharmaceutical company with a biosimilar portfolio (acquired via Hospira) including Inflectra/Remsima, Nivestym, Retacrit and others. Comparable as a broad incumbent with biologics manufacturing scale competing across the same reference molecules.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dr--reddys-laboratories

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dr. Reddy's Biologics